{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T09:44:34Z","timestamp":1782639874823,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,28]]},"DOI":"10.7759\/cureus.111641","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:51:49Z","timestamp":1782636709000},"source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders"],"prefix":"10.7759","author":[{"given":"Indrani","family":"Sarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna P","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Jagdish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif Akhtar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","year":"2018","unstructured":"Alcohol use and burden for 195 countries and territories, 1990-2016. a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018, 392:1015-35. 10.1016\/S0140-6736(18)31310-2","journal-title":"Lancet"},{"key":"ref2","unstructured":"Tobacco and nicotine. (2026). Accessed. June 27, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tobacco."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas DE","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, et al.. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014, 311:1889-900. 10.1001\/jama.2014.3628","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"10","author":"Cahill K","year":"20135","unstructured":"Cahill K, Stevens S, Perera R, et al.. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 20135, 10:1002\/14651858. 10.1002\/14651858.CD009329","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen MK","year":"2022","unstructured":"Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022, 179:625-41. 10.1111\/bph.15677","journal-title":"Br J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler I","year":"1999","unstructured":"Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999, 403:261-80. 10.1002\/(SICI)1096-9861(19990111)403:2&lt;261::AID-CNE8&gt;3.0.CO;2-5","journal-title":"J Comp Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork SC","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015, 4:718-31. 10.1016\/j.molmet.2015.07.008","journal-title":"Mol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff AL","year":"2012","unstructured":"Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012, 153:647-58. 10.1210\/en.2011-1443","journal-title":"Endocrinology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu E","year":"2013","unstructured":"Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013, 8:e77284. 10.1371\/journal.pone.0077284","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061965","article-title":"Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward","volume":"8","author":"Shirazi RH","year":"2013","unstructured":"Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS One. 2013, 8:e61965. 10.1371\/journal.pone.0061965","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f D","year":"2016","unstructured":"Vall\u00f6f D, Maccioni P, Colombo G, et al.. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016, 21:422-37. 10.1111\/adb.12295","journal-title":"Addict Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83118","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"17","author":"Sarma I","year":"2025","unstructured":"Sarma I, Buragohain S, Lahon J, et al.. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Cureus. 2025, 17:e83118. 10.7759\/cureus.83118","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013","unstructured":"Diagnostic and statistical manual of mental disorders. DSM-5. American Psychiatric Association Publishing, Arlington, VA; 2013. 10.1176\/appi.books.9780890425596"},{"key":"ref15","unstructured":"International classification of diseases, 11th revision (ICD-11). (2022). Accessed. Jun 27, 2026: https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases\/international-classification-of-diseases."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref20","unstructured":"Review Manager (RevMan) (Computer program). Version 5.4. (2020). Accessed. June 27, 2026: https:\/\/revman.cochrane.org."},{"key":"ref21","unstructured":"GRADEpro Guideline Development Tool. (2015). Accessed. June 27, 2026: https:\/\/www.gradepro.org\/."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1313","article-title":"Using systematic reviews in guideline development: the GRADE approach","volume":"10","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Akl EA, Sch\u00fcnemann HJ. Using systematic reviews in guideline development: the GRADE approach. Res Synth Methods. 2019, 10:312-29. 10.1002\/jrsm.1313","journal-title":"Res Synth Methods"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen MK","year":"2022","unstructured":"Klausen MK, Jensen ME, M\u00f8ller M, et al.. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022, 7:10.1172\/jci.insight.159863","journal-title":"JCI Insight"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot CS","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, et al.. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025, 82:395-405. 10.1001\/jamapsychiatry.2024.4789","journal-title":"JAMA Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736%2826%2900305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Klausen MK","year":"2026","unstructured":"Klausen MK, Justesen SK, Pedersen JN, et al.. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026, 2:1687-98. 10.1016\/S0140-6736%2826%2900305-3","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking\u00a0cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld S","year":"2023","unstructured":"Lengsfeld S, Burkard T, Meienberg A, et al.. Effect of dulaglutide in promoting abstinence during smoking\u00a0cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 2023, 57:101865. 10.1016\/j.eclinm.2023.101865","journal-title":"EClinicalMedicine"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine L","year":"2021","unstructured":"Yammine L, Green CE, Kosten TR, et al.. Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial. Nicotine Tob Res. 2021, 23:1682-90. 10.1093\/ntr\/ntab066","journal-title":"Nicotine Tob Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1702448","article-title":"The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review","volume":"16","author":"V\u00f6lker KM","year":"2025","unstructured":"V\u00f6lker KM, Prechtl BL, Bormann NL, Choi DS. The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review. Front Pharmacol. 2025, 16:1702448. 10.3389\/fphar.2025.1702448","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie Y","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025, 31:951-62. 10.1038\/s41591-024-03412-w","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo M","year":"2025","unstructured":"L\u00e4hteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025, 82:94-8. 10.1001\/jamapsychiatry.2024.3599","journal-title":"JAMA Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506779-a-systematic-review-and-meta-analysis-evaluating-the-role-of-glp-1-receptor-agonists-in-substance-use-disorders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:51:53Z","timestamp":1782636713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506779-a-systematic-review-and-meta-analysis-evaluating-the-role-of-glp-1-receptor-agonists-in-substance-use-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111641","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}